NASDAQ:INNTInnovate Biopharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Innovate Biopharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.64 -0.08 (-11.11 %) (As of 07/3/2020 04:00 PM ET) Add Compare Share Today's Range$0.61Now: $0.64▼$0.7050-Day Range$0.53MA: $0.59▼$0.6752-Week Range$0.37Now: $0.64▼$1.67Volume3.88 million shsAverage Volume525,982 shsMarket Capitalization$26.45 millionP/E RatioN/ADividend YieldN/ABeta-0.39 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Innovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH). In addition, the company holds rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase III clinical trial. The company has a research collaboration with Massachusetts General Hospital for the treatment of ASH. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Innovate Biopharmaceuticals. Previous Next 2.4 Community Rank Outperform VotesInnovate Biopharmaceuticals has received 203 “outperform” votes. (Add your “outperform” vote.)Underperform VotesInnovate Biopharmaceuticals has received 214 “underperform” votes. (Add your “underperform” vote.)Community SentimentInnovate Biopharmaceuticals has received 51.32% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Innovate Biopharmaceuticals and other stocks. Vote “Outperform” if you believe INNT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe INNT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldInnovate Biopharmaceuticals does not currently pay a dividend.Dividend GrowthInnovate Biopharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Innovate Biopharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.90% of the stock of Innovate Biopharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 5.88% of the stock of Innovate Biopharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Innovate Biopharmaceuticals are expected to grow in the coming year, from ($0.68) to $0.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Innovate Biopharmaceuticals is -0.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Innovate Biopharmaceuticals is -0.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.61 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:INNT Previous Symbol CUSIPN/A CIK1551986 Webwww.innovatebiopharma.com Phone919-275-1933Debt Debt-to-Equity RatioN/A Current Ratio0.35 Quick Ratio0.35Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.27) per share Price / Book-2.37Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-27,050,000.00 Net MarginsN/A Return on EquityN/A Return on Assets-234.42%Miscellaneous Employees8 Outstanding Shares41,325,000Market Cap$26.45 million Next Earnings DateN/A OptionableOptionable NASDAQ:INNT Rates by TradingView Receive INNT News and Ratings via Email Sign-up to receive the latest news and ratings for INNT and its competitors with MarketBeat's FREE daily newsletter. Innovate Biopharmaceuticals (NASDAQ:INNT) Frequently Asked Questions How has Innovate Biopharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Innovate Biopharmaceuticals' stock was trading at $0.4715 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, INNT stock has increased by 35.8% and is now trading at $0.6401. View which stocks have been most impacted by Coronavirus. How were Innovate Biopharmaceuticals' earnings last quarter? Innovate Biopharmaceuticals Inc (NASDAQ:INNT) released its earnings results on Monday, March, 18th. The company reported ($0.11) earnings per share for the quarter, hitting the Zacks' consensus estimate of ($0.11). View Innovate Biopharmaceuticals' earnings history. Has Innovate Biopharmaceuticals been receiving favorable news coverage? Press coverage about INNT stock has trended negative recently, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Innovate Biopharmaceuticals earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news about Innovate Biopharmaceuticals. Who are some of Innovate Biopharmaceuticals' key competitors? Some companies that are related to Innovate Biopharmaceuticals include SUMMIT THERAPEU/S (SMMT), Xeris Pharmaceuticals (XERS), Galmed Pharmaceuticals (GLMD), DiaMedica Therapeutics (DMAC), Endonovo Therapeutics (ENDV), Onconova Therapeutics (ONTX), Otonomy (OTIC), TapImmune (MRKR), Antibe Therapeutics (ATBPF), AcelRx Pharmaceuticals (ACRX), Evoke Pharma (EVOK), Milestone Pharmaceuticals (MIST), Zynerba Pharmaceuticals (ZYNE), Clearside Biomedical (CLSD) and CTI BioPharma (CTIC). View all competitors. What other stocks do shareholders of Innovate Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Innovate Biopharmaceuticals investors own include NIO (NIO), Corbus Pharmaceuticals (CRBP), AcelRx Pharmaceuticals (ACRX), Iterum Therapeutics (ITRM), Axsome Therapeutics (AXSM), Alibaba Group (BABA), Canopy Growth (CGC), Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL) and Avid Bioservices (CDMO). Who are Innovate Biopharmaceuticals' key executives? Innovate Biopharmaceuticals' management team includes the following people: Mr. Sandeep Laumas M.D., CEO & Exec. Chairman (Age 50)Mr. Jay P. Madan M.S., Founder, Pres, Chief Bus. Officer, Interim Principal Fin & Accounting Officer and Director (Age 53)Dr. Christopher P. Prior, Consultant (Age 66)Jerry Gardner M.D., Head of Clinical StrategyDr. Patrick H. Griffin, Chief Medical Officer (Age 64) What is Innovate Biopharmaceuticals' stock symbol? Innovate Biopharmaceuticals trades on the NASDAQ under the ticker symbol "INNT." How do I buy shares of Innovate Biopharmaceuticals? Shares of INNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Innovate Biopharmaceuticals' stock price today? One share of INNT stock can currently be purchased for approximately $0.64. How big of a company is Innovate Biopharmaceuticals? Innovate Biopharmaceuticals has a market capitalization of $26.45 million. Innovate Biopharmaceuticals employs 8 workers across the globe. What is Innovate Biopharmaceuticals' official website? The official website for Innovate Biopharmaceuticals is www.innovatebiopharma.com. How can I contact Innovate Biopharmaceuticals? Innovate Biopharmaceuticals' mailing address is 8480 HONEYCUTT ROAD SUITE 120, RALEIGH NC, 27615. The company can be reached via phone at 919-275-1933 or via email at [email protected] This page was last updated on 7/6/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
